Content area
Recursion Pharmaceuticals Inc (RXRX) - Financial Analysis Review
Recursion Pharmaceuticals Inc (Recursion) is a clinical-stage biotech company. It harnesses the Recursion Operating System (OS) technology platform to develop drugs. The company has a pipeline of internally developed clinical and preclinical programs for precision oncology and genetically induced rare diseases with unmet medical need.
GlobalData's Recursion Pharmaceuticals Inc (RXRX) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.
Recursion Pharmaceuticals Inc Key Recent Developments:
May 05,2025: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 09,2025: Recursion and Enamine Unveil New AI-Enabled Targeted Compound Libraries
Apr 01,2025: Recursion to Participate in Upcoming Investor Conference
Mar 18,2025: Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.